Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07158788

Role of Frailty in Bleeding Risk Prediction in Acute Coronary Syndrome

Incremental Value of Frailty Indices in Bleeding Risk Prediction Among Patients With Acute Coronary Syndrome

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
850 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
65 Years
Healthy volunteers
Not accepted

Summary

Studying the incremental role of frailty in predicting in-hospital, short-term (30 days), and mid-term (6 months) bleeding in ACS patients.

Detailed description

Potent platelet inhibition reduces the risk of thrombotic complications in patients with acute coronary syndromes. Unavoidably, the more potent platelet inhibition increases the risk of bleeding. Bleeding risk can be predicted using the ARC-HBR criteria, the CRUSADE score, ACUITY score, and PRECISE-DAPT score. These conventional risk scores incorporate clinical, laboratory and procedural variables but often overlook patient centered geriatric parameters such as frailty. Frailty is a multidimensional syndrome characterized by decreased reserves and diminished resistance to stressors. It can be assessed using Rockwoods clinical frailty scale, the frailty index, frailty domains and the Fried scale. The association between frailty and bleeding risk in ACS patients is still inadequately studied. We hypothesize that frailty indices would increase the discriminatory power of established standard bleeding risk scores, and would predict bleeding events among ACS patients.

Conditions

Timeline

Start date
2025-10-01
Primary completion
2027-03-01
Completion
2027-09-01
First posted
2025-09-08
Last updated
2025-09-08

Source: ClinicalTrials.gov record NCT07158788. Inclusion in this directory is not an endorsement.